242 related articles for article (PubMed ID: 26599370)
21. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
Low AS; Symmons DP; Lunt M; Mercer LK; Gale CP; Watson KD; Dixon WG; Hyrich KL;
Ann Rheum Dis; 2017 Apr; 76(4):654-660. PubMed ID: 28073800
[TBL] [Abstract][Full Text] [Related]
22. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
[TBL] [Abstract][Full Text] [Related]
23. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
Ke WM; Chen LS; Parng IM; Chen WW; On AW
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
[TBL] [Abstract][Full Text] [Related]
24. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
25. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
[TBL] [Abstract][Full Text] [Related]
26. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
27. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
28. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
29. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
30. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
[TBL] [Abstract][Full Text] [Related]
31. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
32. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
Wadström H; Frisell T; Sparén P; Askling J;
Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
[TBL] [Abstract][Full Text] [Related]
33. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
[TBL] [Abstract][Full Text] [Related]
34. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
37. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
38. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
[TBL] [Abstract][Full Text] [Related]
39. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis.
Hochberg MC; Berry S; Broglio K; Rosenblatt L; Nadkarni A; Trivedi D; Hebden T
Curr Med Res Opin; 2013 Oct; 29(10):1213-22. PubMed ID: 23745516
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]